<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51924">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01870830</url>
  </required_header>
  <id_info>
    <org_study_id>2013-088B</org_study_id>
    <nct_id>NCT01870830</nct_id>
  </id_info>
  <brief_title>Nocturnal Breathing and Sleep in Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude</brief_title>
  <official_title>Nocturnal Breathing and Sleep in Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether nocturnal breathing and sleep of patients
      with chronic obstructive pulmonary disease (COPD) are disturbed during a stay at moderate
      altitude.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized cross-over trial evaluates the hypothesis that patients with chronic
      obstructive pulmonary disease experience nocturnal hypoxemia, periodic breathing and sleep
      disturbances when staying at moderate altitude. Sleep studies and clinical evaluations will
      be performed during 2 days in Zurich (490 m, low altitude baseline) and during 2 days at
      Davos Clavadel (1650 m), and 2 days at Davos Jakobshorn (2590 m).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change in mean nocturnal oxygen saturation from baseline measured at 490 m</measure>
    <time_frame>Change in mean nocturnal oxygen saturation from 490 m baseline during 2 days at 2590 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>mean nocturnal oxygen saturation measured by pulse oximetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in apnea/hypopnea index from baseline measured at 490 m</measure>
    <time_frame>Change in apnea/hypopnea index from 490 m baseline during 2 days at 2590 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>apnea/hypopnea index measured by polysomnography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean nocturnal oxygen saturation from baseline measured at 490 m</measure>
    <time_frame>Change in mean nocturnal oxygen saturation from 490 m baseline during 2 days at 1650 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>apnea/hypopnea measured by polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apnea/hypopnea index from baseline measured at 490 m</measure>
    <time_frame>Change in apnea/hypopnea index from 490 m baseline during stay at 1650 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>apnea/hypopnea index measured by polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective sleep quality from baseline measured at 490 m</measure>
    <time_frame>Change in subjective sleep quality from 490 m during 2 days at 2590 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual analog scale of sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective sleep quality from baseline measured at 490 m</measure>
    <time_frame>Change in subjective sleep quality from 490 m baseline during 2 days at 1650 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual analog scale of sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reaction time from baseline measured at 490 m</measure>
    <time_frame>Change in reaction time from 490 m baseline during 2 days at 2590 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>psychomotor vigilance test reaction time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reaction time from baseline measured at 490 m</measure>
    <time_frame>Change in reaction time from 490 m baseline during 2 days at 1650 m</time_frame>
    <safety_issue>No</safety_issue>
    <description>Psychomotor vigilance test reaction time</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>A: low-intermediate-high altitude</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Altitude exposure sequence A, 490-1650-2590m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: low-high-intermediate altitude</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Altitude exposure sequence B, 490-2590-1650m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: intermediate-high-low altitude</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Altitude exposure sequence C, 1650-2590-490m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: high-intermediate-low altitude</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Altitude exposure sequence D, 2590-1650-490m</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Altitude exposure</intervention_name>
    <description>Stay at different altitudes: 490, 1650, 2590 m</description>
    <arm_group_label>A: low-intermediate-high altitude</arm_group_label>
    <arm_group_label>B: low-high-intermediate altitude</arm_group_label>
    <arm_group_label>C: intermediate-high-low altitude</arm_group_label>
    <arm_group_label>D: high-intermediate-low altitude</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic obstructive pulmonary disease (COPD), GOLD grade 2-3

          -  residents at low altitude (&lt;800 m)

        Exclusion Criteria:

          -  Unstable condition, COPD exacerbation

          -  Mild (GOLD 1) or very severe COPD (GOLD 4)

          -  requirement for oxygen therapy at low altitude residence

          -  hypoventilation

          -  pulmonary hypertension

          -  more than mild or unstable cardiovascular disease

          -  use of drugs that affect respiratory center drive

          -  internal, neurologic or psychiatric disease that interfere with protocol compliance
             including current heavy smoking (&gt;20 cigarettes per day), inability to perform 6 min
             walk test.

          -  previous intolerance to moderate altitude (&lt;2600m).

          -  Exposure to altitudes &gt;1500m for &gt;2 days within the last 4 weeks before the study.

          -  Pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad E Bloch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hsopital Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tsogyal D Latshang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, ZÃ¼rich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad E Bloch, MD</last_name>
    <phone>+41442553828</phone>
    <email>konrad.bloch@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tsogyal D Latshang, MD</last_name>
    <phone>+41442553828</phone>
    <email>tsogyal.latshang@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Pulmonary Division</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konrad E Bloch, MD</last_name>
      <phone>+41442553828</phone>
      <email>konrad.bloch@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Tsogyal D Latshang, MD</last_name>
      <phone>+41442553828</phone>
      <email>tsogyal.latshang@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Konrad E Bloch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsogyal D Latshang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 5, 2013</lastchanged_date>
  <firstreceived_date>June 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
